A combined prognostic serum IL-8 and IL-6 classifier for stage 1 lung cancer in the Prostate Lung Colorectal and Ovarian Cancer Screening Trial

摘要

HypothesisThe advent of LDCT for lung cancer screening will likely lead to an increase in the detection of stage I lung cancer. Presently, these patients are primarily treated with surgery alone and ~ 30% will develop recurrence and die. Biomarkers that can identify patients for whom adjuvant chemotherapy would be a benefit could significantly reduce both patient morbidity and mortality. Herein, we sought to build a prognostic inflammatory-based classifier for stage I lung cancer.